Bill
Bill > H3644
MA H3644
MA H3644Relative to certain genetically targeted drug coverage for Duchenne Muscular Dystrophy
summary
Introduced
04/10/2017
04/10/2017
In Committee
07/31/2018
07/31/2018
Crossed Over
Passed
Dead
12/31/2018
12/31/2018
Introduced Session
190th General Court
Bill Summary
Relative to health insurance coverage for certain genetically targeted drugs for Duchenne muscular dystrophy. Financial Services.
AI Summary
This bill requires health insurance plans in Massachusetts, including those offered by the Group Insurance Commission, MassHealth, individual insurers, and health maintenance organizations, to provide coverage for genetically targeted drugs for Duchenne muscular dystrophy. The key requirements are that the drug must be approved by the FDA, including under the accelerated approval process, and must be determined to be medically necessary by a physician with expertise in Duchenne muscular dystrophy. The coverage cannot be subject to higher deductibles, coinsurance, copayments, or out-of-pocket limits than other benefits. The term "genetically targeted drug" is defined to mean a drug that modulates the function of a gene or its associated product and uses non-replicating nucleic acid or similar compounds to treat patient subgroups with different gene mutations.
Committee Categories
Budget and Finance, Business and Industry, Health and Social Services
Sponsors (1)
Last Action
Amended by substitution of a bill with the same title, H4865 (on 07/31/2018)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://malegislature.gov/Bills/190/H3644 |
| Bill | https://malegislature.gov/Bills/190/H3644.pdf |
Loading...